NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT01026116,A Randomized Trial Comparing EC-wPversus EP-wP as Adjuvant Therapy for Operable Breast Cancer Patients Less Than 40 Years Old,https://clinicaltrials.gov/study/NCT01026116,,COMPLETED,Manifold data revealed that young breast cancer patients are characterized by aggressive clinical history. The purpose of this study is to evaluate the efficacy and safety of different strategies incorporating paclitaxel to anthracycline-based regimens in young breast cancer patients.,NO,Breast Neoplasms,DRUG: Epirubicin|DRUG: Cyclophosphamide|DRUG: Paclitaxel,"disease-free survival, every one year|menstrual resumption rate, Resumption of menses was defined as at least 2 consecutive menstruations, or at least 1 menstruation with a confirmed premenopausal level of FSH and estradiol after chemotherapy, 12 months after chemotherapy","overall survival, every one year",,Fudan University,,FEMALE,ADULT,PHASE3,521,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,SHBCC09007,2009-12,2016-01,2016-12-23,2009-12-04,,2020-05-12,"Department of Breast Surgery, Cancer Hospital, Fudan University, Shanghai, 200032, China",
